Ping Yang

Ping Yang

Auto-generated profile, based on publicly available information

Ping Yang

National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2019 in BMC Immunology
Verified
Journal Article
Open access
PDF file
PYPing Yang
Ping Yang
YGYongqing Guo
Yongqing Guo
YSYao Sun
Yao Sun
BYBin Yu
Bin Yu
HZHaihong Zhang
Haihong Zhang
WKWei Kong
Wei Kong
Active immunotherapy targeting amyloid-β (Aβ) is a promising treatment for Alzheimer’s disease (AD). Numerous preclinical studies and clinical trials demonstrated that a safe and effective AD vaccine should induce high titers of anti-Aβ antibodies while avoiding the activation of T cells specific to Aβ. An untagged Aβ1–6 chimeric protein vaccine against AD based on norovirus (NoV) P particle was expressed in Escherichia coli and obtained by sequential chromatography. Analysis of protein characteristics showed that the untagged Aβ1–6 chimeric protein expressed in soluble form exhibited the highest particle homogeneity, with highest purity and minimal host cell protein (HCP) and residual DNA content. Importantly, the untagged Aβ1–6 chimeric soluble protein could induce the strongest Aβ-specific humoral immune responses without activation of harmful Aβ-specific T cells in mice. The untagged Aβ1–6 chimeric protein vaccine is safe and highly immunogenic. Further research will determine the efficacy in cognitive improvement and disease progression delay.